A detailed history of Heirloom Wealth Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Heirloom Wealth Management holds 17,608 shares of VRTX stock, worth $7.23 Million. This represents 2.66% of its overall portfolio holdings.

Number of Shares
17,608
Previous 17,287 1.86%
Holding current value
$7.23 Million
Previous $8.1 Million 1.07%
% of portfolio
2.66%
Previous 2.73%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$460.0 - $505.78 $147,660 - $162,355
321 Added 1.86%
17,608 $8.19 Million
Q2 2024

Jul 31, 2024

SELL
$392.81 - $485.53 $103,701 - $128,179
-264 Reduced 1.5%
17,287 $8.1 Million
Q1 2024

Apr 24, 2024

SELL
$407.69 - $446.08 $115,783 - $126,686
-284 Reduced 1.59%
17,551 $7.34 Million
Q4 2023

Jan 31, 2024

BUY
$343.0 - $410.68 $131,712 - $157,701
384 Added 2.2%
17,835 $7.26 Million
Q3 2023

Oct 23, 2023

SELL
$338.18 - $362.46 $106,864 - $114,537
-316 Reduced 1.78%
17,451 $6.07 Million
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $231,413 - $259,005
736 Added 4.32%
17,767 $6.25 Million
Q1 2023

Apr 27, 2023

BUY
$283.23 - $323.1 $1.37 Million - $1.57 Million
4,848 Added 39.79%
17,031 $5.37 Million
Q4 2022

Feb 01, 2023

BUY
$285.76 - $321.48 $140,308 - $157,846
491 Added 4.2%
12,183 $3.52 Million
Q2 2022

Aug 10, 2022

BUY
$234.96 - $292.55 $175,280 - $218,242
746 Added 6.82%
11,692 $3.49 Million
Q1 2022

May 17, 2022

SELL
$221.42 - $260.97 $56,240 - $66,286
-254 Reduced 2.27%
10,946 $2.7 Million
Q4 2021

Jan 25, 2022

BUY
$177.01 - $223.45 $1.98 Million - $2.5 Million
11,200 New
11,200 $2.57 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Heirloom Wealth Management Portfolio

Follow Heirloom Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Heirloom Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Heirloom Wealth Management with notifications on news.